Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AryoTrust vs Herceptin in HER2-Positive Breast Cancer
NCT03425656Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Jul 2016
- Primary completion
- Mar 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by AryoGen Biopharma. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03425656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425656.